Therapeutic Role of Bmi-1 Inhibitors in Eliminating Prostate Tumor Stem Cells
Annual rept. 30 Sep 2013 - 29 Sep 2014
RUTGERS - THE STATE UNIV NEW BRUNSWICK NJ
Pagination or Media Count:
Current prostate cancer PCa management calls for identifying novel and more effective therapeutic approaches. Self-renewing prostate tumor-initiating cells TICs hold intrinsic therapy-resistance and account for tumor relapse and progression. BMI-1 Bcell- specific MMLV insertion site-1 regulates stem cell self-renewal, thus, impairing BMI-1 function for TICs-tailored therapies appears to be a promising approach. During the first year of this award and in collaboration with the initiating and other partnering PIs, we developed a time-of-adherence assay to identify CD49bhiCD29hiCD44hi cells as TICs. This year, we identified the first known translational inhibitors of BMI-1 C-209 that target prostate TICs. Employment of this specific BMI-1 inhibitor on patient-derived cells significantly decreased spheroid formation in vitro and prevented tumor initiation in vivo in mice Bertino Lab, thereby diminishing the frequency of TICs. Furthermore, C-209 induced prostate cancer cell senescence, and G1 cell cycle arrest. BMI-1 inhibition, while displaying antitumor activity in mouse xenografts did not exert toxic effects on normal tissues. BMI-1 targeted therapy when combined with taxotere resulted in further antitumor activities. These data offer a paradigm for targeting TICs for a more effective PCa treatment. Therefore, we have accomplished our second year s goal to demonstrate the beneficial effects of targeting prostate TICs in vivo in mice in this synergistic award between three laboratories Sabaawy, Bertino, and Kim to develop a therapeutic strategy for BMI-1 inhibitors in prostate cancer.
- Medicine and Medical Research